VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2020 | Updated analysis of KEYNOTE-426: pembro plus axitinib vs sunitinib in mRCC

Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, discusses the updated analysis of the KEYNOTE-426 trial (NCT02853331). This study evaluated the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for patients with advanced renal cell carcinoma (mRCC). Pembrolizumab in combination with axitinib continued to demonstrate superior and durable antitumor activity versus sunitinib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter